Consensus statement. Workshop on therapeutic resistance in breast cancer: impact of growth factor signalling pathways and implications for future treatment.

@article{Gee2005ConsensusSW,
  title={Consensus statement. Workshop on therapeutic resistance in breast cancer: impact of growth factor signalling pathways and implications for future treatment.},
  author={Julia M. W. Gee and Anthony Howell and William J. Gullick and Christopher C. Benz and Robert Lyndsay Sutherland and R J Santen and Lesley-Ann Martin and Fortunato Ciardiello and William R. Miller and Mitch Dowsett and Peter J. Barrett-Lee and John F. R. Robertson and Stephen R.D. Johnston and Helen E. Jones and Alan E. Wakeling and Ruth Duncan and Robert Ian Nicholson},
  journal={Endocrine-related cancer},
  year={2005},
  volume={12 Suppl 1},
  pages={S1-7}
}
Anti-hormones (notably tamoxifen), chemotherapy and modern radiotherapeutic approaches are invaluable in the management of breast cancer, and collectively have contributed substantially to the improved survival in this disease. Moreover, there is promise that these successes will continue with the emergence of other endocrine agents (for example, aromatase inhibitors and pure anti-oestrogens). However, de novo and acquired resistance comprises a significant problem with all treatment approaches… CONTINUE READING

From This Paper

Topics from this paper.

Citations

Publications citing this paper.
Showing 1-10 of 19 extracted citations

Similar Papers

Loading similar papers…